Rachel Hosking, a young woman grappling with debilitating endometriosis, reflects on her harrowing journey with the disease, which took over five years to diagnose. Now facing significant financial burdens for treatment, she was heartened to hear that a new endometriosis medication will be added to Australia’s Pharmaceutical Benefits Scheme (PBS) on May 1, as part of a $573 million investment by the Labor Government in women’s health.
This new medication, Relugolix with estradiol and norethisterone (marketed as Ryeqo), aims to alleviate symptoms of endometriosis. Currently priced at approximately $140 per month, the PBS subsidy will reduce this to about $32 per month, providing much-needed relief for many Australians—an estimated 830,000 are living with this condition. This subsidy marks the second new treatment for endometriosis introduced by the federal government in 30 years, following the inclusion of Visanne in December 2024.
Hosking, who also studies endometriosis research, welcomes the added drug options, noting that she has tried various treatments without consistent results. The high costs associated with endometriosis make it challenging for patients like her to manage their condition effectively. Currently, Hosking spends around $400 monthly on a combination of medications, physiotherapy, and medical expenses, which limits her treatment options severely.
The impact of endometriosis extends beyond individual suffering, inflicting an economic cost of $9.7 billion annually on Australia. Dr Sneha Wadhwani, Clinical Director at Evoca Women’s Health Clinics, asserts that providing more accessible treatment will not only alleviate financial burdens for patients but will also enhance productivity in the workplace and education, positively influencing the economy.
As the government invests in treatments, it is crucial to continue funding research and support services for endometriosis to improve diagnosis and care. With a significant number of women not responding to initial treatments, offering an array of options is essential for finding effective relief. Hosking emphasises the urgency of addressing these healthcare gaps, expressing hope for a better future for endometriosis patients in Australia, who currently feel “like we’re in the fifth circle of hell.”
Overall, the inclusion of new subsidised treatments signifies a step forward, yet ongoing commitment from the government is required to ensure that those affected can access appropriate care and support, enabling them to better navigate their struggles with this challenging condition.